Series A · Biotech · Vienna, Austria · Founded 2017 · 11–50 employees
VALANX Biotech is an Austrian biotechnology company specializing in next-generation antibody-drug conjugates (ADCs) for cancer therapy. Utilizing its proprietary GoldenSite platform, the company enables precise, site-specific protein conjugation to safely attach cytotoxic drug payloads to target antibodies. This advanced technology improves the uniformity, stability, and overall therapeutic window of ADCs, reducing off-target toxicity. Originally founded as a university spin-off of the Graz University of Technology, the Vienna-based startup raised a 3 million EUR Series A funding round in March 2026. The funding round attracted prominent backers including Foundation Fournier-Majoie and FUJIFILM Corporation, alongside existing venture capital investors.
No open roles listed right now.